Ethyl hydrogen (4-{[4-({2-(diethylcarbamoyl)-4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate → Ethyl hydrogen (4-{[4-({4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-3-methoxy-2-(methylcarbamoyl)phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate

Participants

Reaction Steps

Prepared analogously to Compound 3A using diethyl (4-{[4-({4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-3-methoxy-2-(methyl carbamoyl)phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxy benzyl)phosphonate (Compound 30B). 1H NMR (CD3OD, 400 MHz): δ 8.27 (s, 1H), 8.18 (s, 1H), 7.98 (s, 1H), 7.86 (d, J=8.3 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.66 (d, J=8.8 Hz, 1H), 7.02 (s, 1H), 6.69 (d, J=8.1 Hz, 1H), 4.33 (t, J=6.8 Hz, 2H), 3.88 (s, 3H), 3.82 (m, 2H), 3.64 (s, 3H), 3.59 (t, J=6.1 Hz, 2H), 2.92 (s, 3H), 2.91 (d, J=20.2 Hz, 2H), 2.11 (m, 2H), 1.13 (t, J=7.1 Hz, 3H). MS (ESI): m/z=694.22 [M+H]+. UPLC: tR=1.09 min (UPLC-TOF: polar—3 min).

Provenance & Evidence